# A Sub-study of Cabotegravir (CAB) and Rilpivirine (RPV) in Human Immunodeficiency Viruses (HIV)-Infected Participants

> **NCT05896761** · PHASE3 · COMPLETED · sponsor: **ViiV Healthcare** · enrollment: 118 (actual)

## Conditions studied

- Human Immunodeficiency Virus Type 1 (HIV-1)

## Interventions

- **DRUG:** Cabotegravir Injectable Suspension
- **DRUG:** Rilpivirine Injectable Suspension

## Key facts

- **NCT ID:** NCT05896761
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-28
- **Primary completion:** 2022-08-23
- **Final completion:** 2022-08-23
- **Target enrollment:** 118 (ACTUAL)
- **Last updated:** 2023-09-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05896761

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05896761, "A Sub-study of Cabotegravir (CAB) and Rilpivirine (RPV) in Human Immunodeficiency Viruses (HIV)-Infected Participants". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05896761. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*